579 results
Page 20 of 29
6-K
x2qz57p9 a3on03n6
19 May 11
Teva and Oncogenex to Present Data on Custirsen In Prostate Cancer at the 2011 Asco Annual Meeting
12:00am
6-K
p6fri2eohg 2yrg
17 May 11
Teva and Curetech Announce Positive Phase II Data from CT-011, an Investigational Antibody In Diffuse Large B Cell Lymphoma
12:00am
6-K
wcb7p7b7myso cfd
17 May 11
Teva to Acquire Taiyo
12:00am
6-K
jimxqkms k9q
11 May 11
Current report (foreign)
12:00am
6-K
EX-99.1
319pgzhc
11 May 11
Teva Reports First Quarter 2011 Results
12:00am
6-K
EX-2.1
n2oss2s
3 May 11
Teva Pharmaceutical Industries Limited 6-K
12:00am
6-K
e0x3e3oh 2ytrwu
2 May 11
Teva to Acquire Cephalon In $6.8 Billion Transaction
12:00am
6-K
jgy8r owz
26 Apr 11
Teva Provides Update on Company Activities
12:00am
6-K
f3afitjf10dq3rqxalc7
25 Apr 11
Teva Pharmaceutical Industries LTD. Makes Statement on Define Study Results
12:00am
6-K
rvovtb6 edk0ws
25 Apr 11
Teva to Report First Quarter 2011 Financial Results on May 11, 2011
12:00am
6-K
vbe irvxpbivofcz2h50
25 Apr 11
New Study Demonstrated Significant Reduction In Annualized Relapse Rate and Halting of Disability Progression In MS Patients Switching to Copaxone?
12:00am
6-K
x6lktj5kqd6f45g63n
12 Apr 11
Oral Laquinimod for Multiple Sclerosis Treatment Significantly Reduced Disease Activity and Disability Progression While Providing Good Safety and Tolerability
12:00am
6-K
6kt4 eod9okr
11 Apr 11
Teva Announces Presentation of New Data on Multiple Sclerosis and Parkinson???s Disease Treatments at 2011 American Academy of Neurology Annual Meeting
12:00am
6-K
fv3s lr82v2v4
7 Apr 11
Teva and Oncogenex Present Preclinical Data on the Activity of Its Antisense Compound Custirsen (OGX-011/TV-1011) at the American Association of Cancer Research (Aacr) Annual Meeting 2011
12:00am
6-K
thow6l
24 Mar 11
the Procter & Gamble Company and Teva Pharmaceutical Industries Form Consumer Health Care Partnership
12:00am
6-K
EX-1.1
xre6fxv
21 Mar 11
Current report (foreign)
12:00am
424B5
cbmfe0
17 Mar 11
Prospectus supplement for primary offering
12:00am
6-K
8kd6jhgb b8w0e
17 Mar 11
Teva Announces Pricing of $750,000,000 of Senior Notes
12:00am
424B5
p0h5gg22 1qa9
16 Mar 11
Prospectus supplement for primary offering
12:00am
6-K
ku3rb5o
1 Mar 11
Teva Announces Trial Date In Generic Copaxone? Litigation
12:00am